IL13 and acute promyelocytic leukemia: Although the authors found that a combination treatment of antibodies that targeted PGD2, IL-13, and NKp30 increased survival in a humanized model of APL, further work with other models is needed to tease apart tumour-mediated induction of immunosuppressive ILC2s.